Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase RFWD3 is an enzyme that functions as a key regulator of DNA damage response and repair, particularly at stalled replication forks and double-strand breaks. It facilitates ubiquitination of several damage response proteins, including RPA, RAD51, and p53, which is critical for their removal from chromatin and subsequent repair by homologous recombination. RFWD3 is essential for maintaining genomic stability and protecting cells from DNA damage, and mutations in its gene cause Fanconi anemia complementation group W, a disorder marked by bone marrow failure and cancer susceptibility. RFWD3 is considered a promising therapeutic target due to its central role in DNA damage signaling and repair, especially in conditions where DNA repair mechanisms are compromised[1][2][3][4].
Promotion of ubiquitination of target proteins at replication forks or DNA damage sites; Facilitation of removal of RPA and RAD51 to promote homologous recombination and resolution of DNA damage
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase RFWD3 (RFWD3).